Filtered By:
Management: WHO
Vaccination: Influenza Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 176 results found since Jan 2013.
Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
ConclusionThis GRADE meta-analysis based on a large number of consistent observational studies showed that the mRNA-1273 COVID-19 vaccine is associated with improved clinical effectiveness in IC populations compared with BNT162b2.
Source: Frontiers in Immunology - September 12, 2023 Category: Allergy & Immunology Source Type: research
The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis
Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.08.031. Online ahead of print.ABSTRACTNext generation influenza vaccines are in development and have the potential for widespread health and economic benefits. Determining the potential health and economic impact for these vaccines is needed to drive investment in bringing these vaccines to the market, and to inform which groups public health policies on influenza vaccination should target. We used a mathematical modelling approach to estimate the epidemiological impact and cost-effectiveness of next generation influenza vaccines in England and Wales. ...
Source: Vaccine - August 26, 2023 Category: Allergy & Immunology Authors: Naomi R Waterlow Simon R Procter Edwin van Leeuwen Sreejith Radhakrishnan Mark Jit Rosalind M Eggo Source Type: research
Lessons learned from the COVID-19 pandemic for improved influenza control
Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.08.028. Online ahead of print.ABSTRACTThe World Health Organization noted that COVID-19 vaccination programmes could be leveraged to deliver influenza vaccination. In 2008, the International Federation of Pharmaceutical Manufacturers and Associations' (IFPMA) Influenza Vaccine Supply International Task Force (IVS) developed a survey method using the number of influenza vaccine doses distributed globally to estimate vaccination coverage rates. Seven hundred and ninety-seven million doses were distributed in 2021, representing a 205% increase over the 26...
Source: Vaccine - August 19, 2023 Category: Allergy & Immunology Authors: Abraham Palache John-Kenneth Billingsley Kristin MacLaren Lyn Morgan Steven Rockman Paula Barbosa IFPMA Influenza Vaccine Supply (IFPMA IVS) task force Source Type: research
Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe
Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.07.073. Online ahead of print.ABSTRACTThis review describes the importance of economic evaluations and real-world evidence (RWE) for the assessment of enhanced influenza vaccines for older adults in Europe. Individuals ≥65 years of age are at increased risk of severe influenza outcomes and many countries in Europe recommend enhanced vaccines for this population to mitigate immunosenescence. Some National Immunization Technical Advisory Groups (NITAGs) may preferentially recommend a specific enhanced vaccine, necessitating comparative economic evaluati...
Source: Vaccine - August 7, 2023 Category: Allergy & Immunology Authors: Annie Chicoye Pascal Cr épey Van Hung Nguyen Sergio M árquez-Peláez Maarten Postma Andrea Pugliese Jes ús Ruiz-Aragón Joaquin Mould-Quevedo Source Type: research
Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study
This study aims to evaluate the safety profile and to estimate the incidence of SARS-CoV-2 breakthrough infections in subjects receiving the anti-SARS-CoV-2 and influenza vaccines simultaneously. The study population was represented by healthcare workers (HCWs) of Bari Policlinico General Hospital who received the influenza (Flucelvax Tetra®) and/or anti-SARS-CoV-2 vaccination (BNT162b2 mRNA COVID-19 vaccine, Comirnaty®) either in coadministration or separately in October 2021. Reports of adverse events following immunization (AEFIs) were investigated to study the safety of both vaccines in coadministration and in separa...
Source: Vaccine - August 6, 2023 Category: Allergy & Immunology Authors: L Moscara V Venerito A Martinelli A Di Lorenzo F Toro F Violante S Tafuri P Stefanizzi Source Type: research
Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019
CONCLUSION: Pregnant people are underrepresented in vaccine clinical trials conducted during outbreaks, resulting in underreporting of pregnancy-related outcomes and a lack of protection for pregnant people and neonates from infectious diseases.PMID:37442686 | DOI:10.1016/j.vaccine.2023.06.073
Source: Vaccine - July 13, 2023 Category: Allergy & Immunology Authors: Jamie Minchin Gavin H Harris Sasha Baumann Emily R Smith Source Type: research
Status of New Vaccine Introduction - Worldwide, 2016-2021
This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. By 2021, among 194 countries worldwide, 33 (17%) provided all of these 10 WHO-recommended antigens as part of their routine immunization schedules; only one low-income country had introduced all of these recommended vaccines. Universal hepatitis B birth dose; human papillomavirus vaccine; rotavirus vaccine; and diphtheria, tetanus, and pertussis-containing vaccine first booster dose have been introduced by 57%, 59%, 60%, and 72% of all co...
Source: MMWR Morb Mortal Wkl... - July 6, 2023 Category: Epidemiology Authors: Gurpreet Kaur Rebecca M Casey Jaymin C Patel Paul Bloem Jenny A Walldorf Terri B Hyde Source Type: research
National vaccination policies for health workers - A cross-sectional global overview
CONCLUSION: National policies for vaccinating health workers were complex and context specific with regional and income-level variations. Opportunities exist for developing and strengthening national health worker immunization programmes. Existing health worker immunization programmes might provide a foothold on which broader health worker vaccination policies can be built and strengthened.PMID:37321897 | DOI:10.1016/j.vaccine.2023.04.083
Source: Vaccine - June 15, 2023 Category: Allergy & Immunology Authors: Stacy Young Shoshanna Goldin Laure Dumolard Stephanie Shendale Britney McMurren Helena C Maltezou Shalini Desai Source Type: research
